VNVC Vaccine and Biological Products Factory and Medsintez Pharmaceutical Company (Russian Federation) have signed a comprehensive technology transfer cooperation agreement for the production of new-generation biological drugs to treat various dangerous acute and chronic diseases.

Through this agreement, many advanced biological drug portfolios from the Russian Federation will be transferred for production in Vietnam.

The signing ceremony took place in Hanoi on September 12, witnessed by Russian Minister of Health Mikhail Murashko and Vietnamese Minister of Health Dao Hong Lan.

Immediately after the signing, Medsintez and VNVC will proceed with the steps for transferring Medsintez's advanced biological drug production technology to the VNVC Vaccine and Biological Products Factory.

They will also cooperate in researching, developing, and clinically testing new drugs and vaccines, and distributing high-quality pharmaceutical products from Medsintez in Vietnam and other ASEAN countries.

It is expected that in the coming period, many advanced biological drug portfolios from Medsintez will be transferred for production at the VNVC Vaccine and Biological Products Factory, adhering to high international standards. These include recombinant Albumin, recombinant Insulin, disposable and reusable Insulin pens, diabetes treatments (liraglutide, semaglutide), Heparin anticoagulants (for preventing and treating thrombotic complications causing vascular obstruction leading to stroke, myocardial infarction, pulmonary embolism), the antiviral drug Triazavirin, and follicle-stimulating hormone (used in infertility treatment).

In particular, the two sides will discuss coordinating clinical research on the antiviral drug Triazavirin for the treatment of Dengue fever, a disease that causes hundreds of thousands of cases and dozens of deaths annually in Vietnam.